LevelJump Healthcare Corp. Reports Third Quarter 2023 Results

Rhea-AI Summary

LevelJump Healthcare Corp. (TSXV: JUMP) (OTCQB: JMPHF) (FSE: 75J) reports Q3 fiscal results with a 31% revenue increase to $2,856,044 and a 14% gross profit increase to $739,479. The company aims to sustain revenue growth by leveraging established Diagnostic Centers and delivering value to shareholders.

Toronto, Ontario--(Newsfile Corp. - November 29, 2023) - LevelJump Healthcare Corp. (TSXV: JUMP) (OTCQB: JMPHF) (FSE: 75J) ("LevelJump" or the "Company"), a Canadian leader in B2B telehealth solutions, is pleased to announce today it has reported financial results for the third fiscal quarter ended September 30, 2023. All amounts are expressed in Canadian dollars.

Financial and Operational Highlights

• Revenues from operations were $2,856,044 for the third quarter, an increase of 31% from the prior year.

• Gross profits from operations were $739,479 for the third quarter, an increase of 14% from the prior year.

"Despite a challenging market and economic landscape, we progressed on our organic growth and our acquisition plan as well as expanded our teleradiology services to Saskatchewan, solidifying JUMP as a national provider," said Mitch Geisler, CEO. "Looking ahead, our immediate priority is to sustain revenue growth by leveraging both our recently acquired and established Diagnostic Centers while consistently delivering value to our shareholders."

Non-IFRS Financial Measures

This news release contains financial terms (such as adjusted EBITDA) that are not considered in IFRS. Such financial measures, together with measures prepared in accordance with IFRS, provide useful information to investors and shareholders, as management uses them to evaluate the operating performance of the Company. The Company's determination of these non-IFRS measures may differ from other reporting issuers, and therefore are unlikely to be comparable to similar measures presented by other companies. Further, these non-IFRS measures should not be considered in isolation or as a substitute for measures of performance or cash flows prepared in accordance with IFRS. These financial measures are included because management uses this information to analyze operating performance and liquidity.

Adjusted EBITDA & Annual Revenue Run Rate

Management believes adjusted EBITDA is a useful supplemental measure to determine the Company's ability to generate cash available for working capital, capital expenditures, debt repayments, interest expense and income taxes.

EBITDA refers to net income (loss) determined in accordance with IFRS, before depreciation and amortization, net interest expense (income), income tax expense (recovery) and extraordinary items. The Company defines adjusted EBITDA as EBITDA, plus stock-based compensation expense, restructuring, fair value adjustments, listing expense and transaction costs, impairment, and finance income.

A reconciliation of adjusted EBITDA to net income (loss) is as follows.

		3 Months ended September 30, 2023			3 Months ended September 30, 2022			9 Months ended September 30, 2023			9 Months ended September 30, 2023
Revenues		2,856,044			2,296,187			9,015,126			6,611,990
Cost of Sales		2,116,565			1,649,041			6,400,165			4,818,527
Gross Profit		739,479			647,146			2,614,962			1,793,463
Operating Expenses		947,065			813,637			3,180,811			2,499,092
Net Profit		(207,586	)		(166,491	)		(565,850	)		(705,629	)
Other Income		-			188			116,604			102,958
Other Expenses		1,386,054			43,315			1,579,627			134,545
Net Income/(Loss)		(1,593,641	)		(209,618	)		(2,028,873	)		(737,216	)
add back
Finance costs		59,411			40,219			176,587			100,358
Amortization and Depreciation		129,059			51,335			341,251			145,368
EBITDA		(1,405,171	)		(118,064	)		(1,511,034	)		(491,490	)
add back
Stock Based compensation		-			36,833			-			256,499
Broker Commissions		-			-			66,500			20,201
Investment losses		1,329,876			-			1,329,876			2,971
Other		(3,232	)		3,096			6,664			11,015
One time nonrecurring operating expenses		100,000			100,000			100,000			100,000
subtract other Income		-			188			116,604			102,958
Adjusted EBITDA		21,473			21,677			(124,598	)		(203,762	)

 

About LevelJump Healthcare

LevelJump Healthcare Corp., (TSXV: JUMP) provides telehealth solutions to client hospitals and imaging centers through its Teleradiology division, as well as in person radiology services through its IHF's (Independent Healthcare Facilities). JUMP focuses primarily on critical care for urgent and emergency patients, establishing integral relationships in the communities we serve.

ON BEHALF OF THE BOARD OF DIRECTORS OF
LEVELJUMP HEALTHCARE CORP.

Mitchell Geisler
Chief Executive Officer

Caitlin-Robyn Densmore
Investor Relations Manager
Caitlin.Densmore@leveljumphealthcare.com
(437) 214-1568

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION

This news release contains "forward-looking information" within the meaning of applicable securities laws relating to the Company's business plans and the outlook of the Company's industry. Although the Company believes, in light of the experience of its officers and directors, current conditions and expected future developments and other factors that have been considered appropriate, that the expectations reflected in this forward-looking information are reasonable, undue reliance should not be placed on them because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. The statements in this press release are made as of the date of this release and the Company assumes no responsibility to update them or revise them to reflect new events or circumstances other than as required by applicable securities laws. The Company undertakes no obligation to comment on analyses, expectations or statements made by third-parties in respect of the Company, Canadian Teleradiology Services, Inc., their securities, or their respective financial or operating results (as applicable).

Neither the Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Exchange) accepts responsibility for the adequacy or accuracy of this release.

The securities being offered have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") or any U.S. state securities laws, and may not be offered or sold in the United States or to, or for the account or benefit of, United States persons absent registration or an applicable exemption from the registration requirements of the U.S. Securities Act and applicable U.S. state securities laws. This press release does not constitute an offer to sell or the solicitation of an offer to buy securities in the United States, nor in any other jurisdiction.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/189039

FAQ

What are LevelJump Healthcare Corp.'s (JUMP) Q3 fiscal results?

LevelJump Healthcare Corp. (JUMP) reported $2,856,044 in revenues and $739,479 in gross profits for the third quarter, marking a 31% and 14% increase, respectively.

What is LevelJump Healthcare Corp.'s (JUMP) strategy for revenue growth?

LevelJump Healthcare Corp. (JUMP) aims to sustain revenue growth by leveraging established Diagnostic Centers and consistently delivering value to shareholders.

What is the non-IFRS financial measure used by LevelJump Healthcare Corp. (JUMP)?

The non-IFRS financial measures used by LevelJump Healthcare Corp. (JUMP) include adjusted EBITDA and annual revenue run rate, which are considered useful supplemental measures to analyze operating performance and liquidity.

How does LevelJump Healthcare Corp. (JUMP) define adjusted EBITDA?

LevelJump Healthcare Corp. (JUMP) defines adjusted EBITDA as EBITDA, plus stock-based compensation expense, restructuring, fair value adjustments, listing expense and transaction costs, impairment, and finance income.